Affinity Matrix HPLC for AAV Capsid Titer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting the capsid titer and determining the ratio of full and empty capsids of adeno-associated viruses (AAVs) are inefficient, requiring labor-intensive processes, large sample quantities, and often result in poor accuracy and precision.
Innovation Solution
The use of an affinity matrix in an HPLC process for the detection of AAV capsid titer and determination of capsid content ratio, allowing for direct analysis of non-purified samples and simultaneous detection and purification of AAV capsids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ELISA method is used for capsid quantification, then high specificity is achieved, but turnaround time increases to 3-4 hours and labor intensity increases
Solution Approach 1:
The invention extracts the detection function from the complex ELISA multi-step process and integrates it into a single HPLC-based affinity chromatography step. The affinity matrix selectively binds AAV capsids while allowing other components to pass through, and fluorescence detection directly quantifies the bound capsids, eliminating the need for separate antibody incubation and colorimetric development steps.
Solution Approach 2:
The invention merges purification and detection functions into a single HPLC affinity chromatography step. The affinity matrix both purifies AAV capsids from non-purified samples and enables their quantification through fluorescence detection, combining what were previously separate operations into one integrated process that reduces turnaround time while maintaining specificity.
2Measurement precision
If SEC-MALS method is used for capsid titer detection, then accurate quantification is achieved, but sample purification is required beforehand increasing process complexity
Solution Approach 1:
The invention performs preliminary purification action within the HPLC affinity chromatography step itself. The affinity matrix pre-cleans the sample by selectively binding AAV capsids and retaining other components in the flow-through, so that accurate fluorescence detection can be performed directly on the bound fraction without requiring prior sample purification.
3Measurement precision
If PCR-based methods are used for genome titer quantification, then genome content is measured, but capsid protein titer cannot be determined and sample treatment is required
Solution Approach 1:
The invention uses fluorescence detection as an intermediary that directly measures capsid protein without requiring DNA extraction or amplification. The fluorescence signal from the affinity-bound capsids provides a direct readout of capsid protein titer, while the same bound fraction can subsequently be analyzed by PCR for genome content, eliminating the need for separate sample treatments.
4Measurement precision
If antibody-based methods are used for capsid detection, then high specificity is achieved, but sample volume requirements increase and non-purified samples cannot be analyzed
Solution Approach 1:
The invention applies local quality by creating a localized high-affinity binding environment on the affinity matrix where AAV capsids are selectively concentrated from the bulk sample. This localized concentration effect allows accurate detection of capsids in non-purified samples with minimal sample volume, as the affinity matrix creates a focused detection zone rather than requiring uniform antibody distribution throughout the entire sample volume.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a rapid, efficient, and reliable means of detecting AAV capsid titer and determining capsid content ratio, with improved accuracy and precision compared to existing methods, and allows for the collection of native AAV particles for further applications.
Implementation Method 1
loading an AAV sample onto an affinity matrix
Implementation Method 2
detecting the AAV capsid titer in the eluate with a fluorescence detection system
Data Source
AI summary
The present invention relates to a method for the detection of the capsid titer of an adeno-associated virus (AAV) and to a method for the determination of the ratio of full and empty capsids of an AAV by the use of an affinity matrix.